reports
- Jonathan Moreland
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PAYC PAYCOM SOFTWARE INC.
MOFG MIDWESTONE FINANCIAL GROUP
AHH ARMADA HOFFLER PROPERTIES INC.
INMB INMUNE BIO
GRX INC.
VRDN THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CTLP VIRIDIAN THERAPEUTICS INC
BIGZ CANTALOUPE
BUKS INC.
GLSI BLACKROCK INNOVATION AND GROWTH TST
BMEZ BUTLER NATIONAL CORP
PEO GREENWICH LIFESCIENCES INC
DV BLACKROCK HEALTH SCIENCES TERM TRUST
BNTC PETROLEUM & RESOURCES CORPORATION
DEVRY INC.
BENITEC BIOPHARMA INC
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib ...
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses Erasca to host virtual R&D update for investors on Thursday, October 24, 2024, at 8:30 AM ET SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasc...
Erasca to Present at Upcoming Investor Conferences in September
Erasca to Present at Upcoming Investor Conferences in September SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in September 2024 and will also participate in one-on-one investor meetings. 22nd Annual Morgan Stanley Global Healthcare ConferenceLocation: New York Marriott Marquis, New York, NYFormat: Fireside...
Erasca Reports Second Quarter 2024 Business Updates and Financial Resu...
Erasca Reports Second Quarter 2024 Business Updates and Financial Results In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 registrational trial in patients with NRASm melanoma; randomized data for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $460 million as of June 30, 2024 is expected to fund operations into H1 2027 SA...
- Jonathan Moreland
SAIA SAIA INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
PBPB POTBELLY CORP.
OEC ORION ENGINEERED CARBONS SA
NEOG NEOGEN CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
KVHI KVH INDUSTRIES INC.
INTC INTEL CORPORATION
HTGC HERCULES CAPITAL INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
FPI FARMLAND PARTNERS REIT
FOXF FOX FACTORY HOLDING CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
EHTH EHEALTH INC.
CRK COMSTOCK RESOURCES INC.
CHCT COMMUNITY HEALTHCARE TRUST INCORPORATED
BXMT BLACKSTONE MORTGAGE TRUST INC. CLASS A
AGCO AGCO CORPORATION
TEX TEREX CORPORATION
MEDP MEDPACE HOLDINGS INC.
ATEC ALPHATEC HOLDINGS INC.
MGM MGM RESORTS INTERNATIONAL
RIGN TRANSOCEAN LTD.
LIND LINDBLAD EXPEDITIONS HOLDINGS
AMBC AMBAC FINANCIAL GROUP INC.
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
DIS THE WALT DISNEY COMPANY
AXR AMREP
VCNX VACCINEX
STRA STRATEGIC EDUCATION INC.
PFIS PEOPLES FINANCIAL SERVICES CORP.
CMTV COMMUNITY BANCORP INC. VT
TSLX SIXTH STREET SPECIALTY LENDING
ONEW INC.
AZYO ONEWATER MARINE
MPLN AZIYO BIOLOGICS
CTOS MULTIPLAN CORP CLASS A
CVRX CUSTOM TRUCK ONE SOURCE
RPID INC.
GLSI CVRX
MBLY INC.
ATMU RAPID MICRO BIOSYSTEMS INC
GT GREENWICH LIFESCIENCES INC
NBBK MOBILEYE GLOBAL INC
MOBQ ATMUS FILTRATION TECHNOLOGIES INC
GOODYEAR TIRE & RUBBER CO.
NB BANCORP INC.
MOBIQUITY TECHNOLOGIES
INC.
- Jonathan Moreland
OEC ORION ENGINEERED CARBONS SA
HTGC HERCULES CAPITAL INC.
FPI FARMLAND PARTNERS REIT
EHTH EHEALTH INC.
CLFD CLEARFIELD INC.
BXMT BLACKSTONE MORTGAGE TRUST INC. CLASS A
AGCO AGCO CORPORATION
ATEC ALPHATEC HOLDINGS INC.
AMBC AMBAC FINANCIAL GROUP INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
MPLN MULTIPLAN CORP CLASS A
CVRX CVRX
RSVR INC.
BIGZ RESERVOIR MEDIA
GLSI INC.
ATMU BLACKROCK INNOVATION AND GROWTH TST
MIO GREENWICH LIFESCIENCES INC
MOBQ ATMUS FILTRATION TECHNOLOGIES INC
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
MOBIQUITY TECHNOLOGIES
INC.
- Jonathan Moreland
RHP RYMAN HOSPITALITY PROPERTIES INC.
PBPB POTBELLY CORP.
PBF PBF ENERGY INC. CLASS A
PAYC PAYCOM SOFTWARE INC.
OEC ORION ENGINEERED CARBONS SA
NEOG NEOGEN CORPORATION
INTC INTEL CORPORATION
CRK COMSTOCK RESOURCES INC.
MEDP MEDPACE HOLDINGS INC.
NINE NINE ENERGY SERVICE INC
VCNX VACCINEX
PFIS PEOPLES FINANCIAL SERVICES CORP.
ZM ZOOM VIDEO COMMUNICATIONS
TSLX INC.
MPLN SIXTH STREET SPECIALTY LENDING
GEVO INC.
CTOS MULTIPLAN CORP CLASS A
RPID GEVO
GLSI CUSTOM TRUCK ONE SOURCE
INC.
RAPID MICRO BIOSYSTEMS INC
GREENWICH LIFESCIENCES INC
Atlassian Announces Fourth Quarter and Fiscal Year 2024 Results
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced financial results for its fourth quarter and fiscal year 2024. A shareholder letter was posted on Atlassian’s Work Life blog at and in the Investor Relations section of Atlassian’s website at . Fourth Quarter Fiscal Year 2024 Earnings Results “This past year we’ve once again proved to ourselves that we can accomplish big things. We grew revenue to $4.4 billion, generated free cash flow of over $1.4 billion, and surged past...
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 int...
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hos...
- Jonathan Moreland
Atlassian Appoints Scott Belsky, Adobe Chief Strategy Officer, to Boar...
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced it is appointing Scott Belsky to its Board of Directors effective August 1, 2024. Scott is the Chief Strategy Officer and Executive Vice President, Design & Emerging Products, at Adobe (NASDAQ: ADBE), a leader in creative, digital document and digital experience technology. “I'm excited for Scott to bring his deep strategy and product experience to our Board. He's built loveable products used by millions of people around the ...
Atlassian Achieves FedRAMP “In Process” Designation
TEAM Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, announced today that it has achieved Federal Risk and Authorization Management Program (FedRAMP) “In Process” status and is now listed on the . This important milestone brings Atlassian one step closer to achieving FedRAMP Moderate Authority to Operate (ATO) - which is currently estimated for the first quarter of calendar year 2025 - and is a significant part of Atlassian’s broader investment in supporting the U.S. public sector. The company...
Atlassian Announces Date for Fourth Quarter and Fiscal Year 2024 Finan...
TEAM, Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced that it will release financial results for its fourth quarter and fiscal year ended June 30, 2024 after market close on Thursday, August 1, 2024. Atlassian will host a webcast and conference call to discuss the financial results at 2:00 P.M. Pacific Time. In conjunction with its earnings press release, Atlassian will post a shareholder letter to the Investor Relations section of its website at . Webcast Details When: Thur...
- Jonathan Moreland
WIRE ENCORE WIRE CORPORATION
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PSEC PROSPECT CAPITAL CORPORATION
NFBK NORTHFIELD BANCORP INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
EGBN EAGLE BANCORP INC.
CVBF CVB FINANCIAL CORP.
CRMT AMERICA'S CAR-MART INC.
BEN FRANKLIN RESOURCES INC.
AMSWA AMERICAN SOFTWARE INC. CL A
ACRS ACLARIS THERAPEUTICS INC.
CLOV CLOVER PAKISTAN LTD.
CLI MACK-CALI REALTY CORPORATION
NAD NUVEEN QUALITY MUNICIPAL INCOM
OPOF OLD POINT FINANCIAL CORP.
FRD FRIEDMAN INDUSTRIES INC.
XOM EXXON MOBIL CORPORATION
DMLP DORCHESTER MINERALS L.P.
NHF NEXPOINT CREDIT STRATEGIES FUN
CLIR CLEARSIGN TECHNOLOGIES CORP
CLF CLIFFS NATURAL RESOURCES INC.
LILA LIBERTY LATIN AMERICA A
PRPL PURPLE INNOVATION
VICR INC.
VPLM VICOR CORP.
GOSS VOIP PAL.COM INC.
ADV GOSSAMER BIO
DMAC ADVANTAGE SOLUTIONS INC (A)
GRNT DIAMEDICA THERAPEUTICS INC.
TSHA GRANIT SKOPKE
NUVB TAYSHA GENE THERAPIES
PFX NUVATION BIO INC (A)
AVTE PHENIXFIN CORP
AUID AEROVATE THERAPEUTICS
NSPR INC.
ACHR IPSIDY INC.
ASLE INSPIREMD INC
BIGZ ARCHER AVIATION INC
GLSI AERSALE CORP
LNKB BLACKROCK INNOVATION AND GROWTH TST
RH GREENWICH LIFESCIENCES INC
IRON LINKBANCORP INC
VFC RESTORATION HARDWARE HOLDINGS INC
AEI DISC MEDICINE INC
EP VF CORPORATION
PYYX ALSET INC.
GRUSF EMPIRE PETROLEUM CORP
PEO PYXUS INTERNATIONAL INC
DMA GROWN ROGUE INTERNATIONAL INC.
NRBO PETROLEUM & RESOURCES CORPORATION
ARDS DESTRA MULTI ALTERNATIVE FUND
MXF NEUROBO PHARMACEUTICALS INC
ARIDIS PHARMACEUTICALS
INC.
THE MEXICO FUND
INC.
Greenwich LifeSciences Set to Join Russell 2000 Index Again
Greenwich LifeSciences Set to Join Russell 2000 Index Again STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as...
- Jonathan Moreland
WSR WHITESTONE REIT
WIRE ENCORE WIRE CORPORATION
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PEB PEBBLEBROOK HOTEL TRUST
NFBK NORTHFIELD BANCORP INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
EGBN EAGLE BANCORP INC.
CVBF CVB FINANCIAL CORP.
CRMT AMERICA'S CAR-MART INC.
BEN FRANKLIN RESOURCES INC.
ACRS ACLARIS THERAPEUTICS INC.
CLI MACK-CALI REALTY CORPORATION
NSA NATIONAL STORAGE AFFILIATES TRUST
OPOF OLD POINT FINANCIAL CORP.
FRD FRIEDMAN INDUSTRIES INC.
ZOM ZOMEDICA PHARMACEUTICALS CORP
HWKN HAWKINS INC.
GBDC GOLUB CAPITAL BDC INC.
XOM EXXON MOBIL CORPORATION
DMLP DORCHESTER MINERALS L.P.
ICCH ICC HOLDINGS
NHF NEXPOINT CREDIT STRATEGIES FUN
CLF CLIFFS NATURAL RESOURCES INC.
NWPP NEW PEOPLES BANKSHARES INC.
VPLM VOIP PAL.COM INC.
DOMO DOMO INCORPORATED
RZLT REZOLUTE
KRON INC.
CSU KRONOS BIO
GRNT CAPITAL SENIOR LIVING
NUVB GRANIT SKOPKE
PFX NUVATION BIO INC (A)
AVTE PHENIXFIN CORP
CLOV AEROVATE THERAPEUTICS
ASLE INC.
GLSI CLOVER HEALTH INV CORP
LNKB AERSALE CORP
IRON GREENWICH LIFESCIENCES INC
VFC LINKBANCORP INC
UHG DISC MEDICINE INC
FTREV VF CORPORATION
AEI UNITED HOMES GROUP INC
CATX FORTREA HOLDINGS INC.
PYYX ALSET INC.
PRSO PERSPECTIVE THERAPEUTICS
GRUSF INC.
NUZE PYXUS INTERNATIONAL INC
PEO PERASO INC.
BNED GROWN ROGUE INTERNATIONAL INC.
NUZEE INC.
PETROLEUM & RESOURCES CORPORATION
BARNES & NOBLE EDUCATION INC.
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafen...
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomized Stage 1 readout for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025 SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-sta...
Greenwich LifeSciences Announces $2.5 Million Private Placement
Greenwich LifeSciences Announces $2.5 Million Private Placement STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per sha...
Erasca to Present at Upcoming Investor Conferences in June
Erasca to Present at Upcoming Investor Conferences in June SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings. Jefferie...
Erasca Announces Closing of Underwritten Offering of Common Stock and ...
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.